These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493 [TBL] [Abstract][Full Text] [Related]
5. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Stone KB; Oddis CV; Fertig N; Katsumata Y; Lucas M; Vogt M; Domsic R; Ascherman DP Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431 [TBL] [Abstract][Full Text] [Related]
6. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950 [TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235 [TBL] [Abstract][Full Text] [Related]
10. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871 [TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of inflammatory myopathies: a review. Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Kryštůfková O; Hulejová H; Mann HF; Pecha O; Půtová I; Ekholm L; Lundberg IE; Vencovský J Arthritis Res Ther; 2018 Jul; 20(1):158. PubMed ID: 30053824 [TBL] [Abstract][Full Text] [Related]
13. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Kryštůfková O; Barbasso Helmers S; Venalis P; Malmström V; Lindroos E; Vencovský J; Lundberg IE Arthritis Res Ther; 2014 Oct; 16(5):454. PubMed ID: 25301447 [TBL] [Abstract][Full Text] [Related]
14. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Cruellas MG; Viana Vdos S; Levy-Neto M; Souza FH; Shinjo SK Clinics (Sao Paulo); 2013 Jul; 68(7):909-14. PubMed ID: 23917652 [TBL] [Abstract][Full Text] [Related]
15. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies. Muro Y; Ishikawa A; Sugiura K; Akiyama M Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Pinal-Fernandez I; Parks C; Werner JL; Albayda J; Paik J; Danoff SK; Casciola-Rosen L; Christopher-Stine L; Mammen AL Arthritis Care Res (Hoboken); 2017 Feb; 69(2):263-270. PubMed ID: 27111848 [TBL] [Abstract][Full Text] [Related]
17. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. Frank MB; McCubbin V; Trieu E; Wu Y; Isenberg DA; Targoff IN J Autoimmun; 1999 Mar; 12(2):137-42. PubMed ID: 10047434 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170 [TBL] [Abstract][Full Text] [Related]
19. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. López De Padilla CM; Crowson CS; Hein MS; Strausbauch MA; Aggarwal R; Levesque MC; Ascherman DP; Oddis CV; Reed AM Clin Exp Rheumatol; 2015; 33(5):655-63. PubMed ID: 26446265 [TBL] [Abstract][Full Text] [Related]
20. Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Hulejová H; Kryštůfková O; Mann H; Klein M; Pavlíčková K; Zámečník J; Vencovský J; Šenolt L Clin Exp Rheumatol; 2016; 34(2):222-9. PubMed ID: 26886056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]